Henry Meds vs Yucca Health (2026): prices, structure, verdict

On tirzepatide, Yucca Health↗ is cheaper: $258 versus $349 a month all-in — a $91 monthly gap, $1,092 across a year of maintenance dosing.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, Yucca Health is cheaper: $146 versus $179 a month all-in — a $33 monthly gap, $396 across a year of maintenance dosing.

§ Side by side

§ Each record, read aloud

The two records, condensed

Henry Meds: the record, condensed

On tirzepatide, the number that matters at Henry Meds is $349 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

To place the number: #10 of 17 verified programs, with the floor $134/month below at NexLife↗ ($215); the approved-product yardstick (Zepbound (LillyDirect↗)) sits at $449, so the compounded case here is worth $100 a month. A year at this figure: $4,188 monthly-billed.

On semaglutide, the number that matters at Henry Meds is $179 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at Henry Meds is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $179 is the whole subscription, which makes Henry Meds unusually easy to compare and unusually easy to leave.

Context for that figure: it ranks #9 of 20 in the verified semaglutide index — $46/month above the floor (Oak Longevity, $133) — and sits $170 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $2,148.

Operationally at Henry Meds: shipping included; commitment none month-to-month; cancellation check terms before prepaying; pharmacy not publicly named — ask in writing before paying; states: most states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Henry Meds page · visit Henry Meds ↗

Yucca Health: the record, condensed

On tirzepatide, the number that matters at Yucca Health is $258 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

There is no membership line. $258 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

To place the number: #2 of 17 verified programs, with the floor $43/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $191 a month. A year at this figure: $3,096 monthly-billed.

Start with the load-bearing figure: $146 a month, all-in, is what Yucca Health charges for semaglutide at the 2.4 mg basis. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Context for that figure: it ranks #2 of 20 in the verified semaglutide index — $13/month above the floor (Oak Longevity, $133) — and sits $203 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $1,752.

Operationally at Yucca Health: shipping included; commitment 6-month term; cancellation 6-month term applies; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the Yucca Health page · visit Yucca Health ↗

Tirzepatide: the duel in full

Put the two tirzepatide figures side by side and hold them there: Yucca Health at $258, Henry Meds at $349 — a $91 monthly spread that compounds to $1,092 over a maintenance year and $2,184 over two.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $91 gap is exactly what it appears to be.

Semaglutide: the duel in full

The semaglutide arithmetic between these two is short: $146 (Yucca Health) against $179 (Henry Meds). $33 a month sounds survivable; $396 a year is a decision.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $33 gap is exactly what it appears to be.

A way to feel the $91 monthly gap: over a year it funds 4.2 extra months at Yucca Health’s own rate — the difference is not decoration, it is medication. Over two years it compounds to $2,184, which is the horizon at which structural details (prepaid ladders, membership drag, dose-tier repricing) start mattering more than the sticker itself.

Run the same two programs on the committed basis: Henry Meds $349/mo month-to-month against Yucca Health $258/mo month-to-month. The order holds: Yucca Health leads on both readings, so plan structure sharpens the verdict here rather than reversing it. Whichever basis fits your commitment level, the upfront totals above are the honest units.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: Henry Meds $1,047 monthly; Yucca Health $774 monthly — best path favors Yucca Health by $273. 6 months: Henry Meds $2,094 monthly; Yucca Health $1,548 monthly — best path favors Yucca Health by $546. 12 months: Henry Meds $4,188 monthly; Yucca Health $3,096 monthly — best path favors Yucca Health by $1,092. 24 months: Henry Meds $8,376 monthly; Yucca Health $6,192 monthly — best path favors Yucca Health by $2,184.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

The same clock, on semaglutide

3 mo: Henry Meds $537 vs Yucca Health $438 — $99 to Yucca Health. 6 mo: Henry Meds $1,074 vs Yucca Health $876 — $198 to Yucca Health. 12 mo: Henry Meds $2,148 vs Yucca Health $1,752 — $396 to Yucca Health. 24 mo: Henry Meds $4,296 vs Yucca Health $3,504 — $792 to Yucca Health.

Same rules as above: prepaid figures are upfront commitments, and the 24-month lines extend the 12-month rate as a stated assumption. Where the two molecules crown different winners between these two programs, that split is itself the finding — molecule choice and provider choice are separate decisions.

§ Structure vs structure

Everything besides the price

Coverage: Henry Meds publishes “most states”; Yucca Health publishes “not published” — for anything short of an explicit 50-state claim, intake is the final word.

Neither names its pharmacy publicly — the single most useful disclosure in this category, missing on both sides; ask each, in writing, before paying either.

Exit terms: Henry Meds — none month-to-month; check terms before prepaying. Yucca Health — 6-month term; 6-month term applies.

Evidence: Henry Meds third-party reported (captured 2026-08-05); Yucca Health source-verified (2026-08-05).

The pattern worth internalizing: in this market, structural honesty and price honesty travel together. Programs that publish pharmacies and state lists tend to publish real maintenance prices; programs that hide one usually hide the other.

In the full tirzepatide index these two sit at #10 and #2 of 17: between them lie 7 other programs, and the whole ladder is at cheapest tirzepatide providers. In the full semaglutide index these two sit at #9 and #2 of 20: between them lie 6 other programs, and the whole ladder is at cheapest semaglutide providers.

§ If you move

Switching between Henry Meds and Yucca Health

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (Henry Meds: check terms before prepaying; Yucca Health: 6-month term applies) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings